Neeraj Agarwal, Professor of Medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), shared on X:
“Just in CA: Cancer Journal.
Comprehensive review of efficacy and safety data of PARP inhibitors across cancer types prostate cancer, ovarian cancer, breast cancer and others
A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors
Authors: Chadi Hage Chehade et al.
Neeraj Agarwal is a Professor of Medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program, and the Center of Investigational Therapeutics (CIT) at the HCI.
Dr. Agarwal is an Advisor to the Oncology Drug Advisory Committee and the United States Food and Drug Administration, leads early therapeutics in the SWOG genitourinary cancers committee, and is the Chief Editor of ASCO Daily News.
